المؤلفون: Dmitry E. Karateev, Elena L. Luchikhina

المصدر: Терапевтический архив, Vol 96, Iss 5, Pp 543-550 (2024)

مصطلحات موضوعية: spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, interleukin-17a, netakimab, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/viewFile/633109/147927Test; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/580af92ef24c4ab5ab2b1752e7de2417Test

المؤلفون: Alexey D. Meshkov, Natalya M. Vorobyeva, Valentina S. Ostapenko, Valentina S. Pykhtina, Viktoriya I. Ruzanova, Olesia A. Perlova, Irina S. Kordyukova, Anton V. Naumov, Natalia O. Khovasova, Olga N. Tkacheva

المصدر: Терапевтический архив, Vol 95, Iss 12, Pp 1172-1178 (2023)

مصطلحات موضوعية: netakimab, interleukin-17a inhibitor, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, genetically engineered biological agents, real-world practice, Medicine

وصف الملف: electronic resource

العلاقة: https://ter-arkhiv.ru/0040-3660/article/viewFile/626344/142222Test; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test

الوصول الحر: https://doaj.org/article/0b180aaf6275439fbd85afc8cf73e2eeTest

المؤلفون: M. I. Kurdina, N. G. Kolenko, М. И. Курдина, Н. Г. Коленько

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2024); 144-152 ; Медицинский Совет; № 2 (2024); 144-152 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: нетакимаб, IL-17 inhibitor, biological therapies, netakimab, генно-инженерная биологическая терапия, ингибитор ИЛ-17

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/8139/7186Test; Samman PD, Fenton DA. The nails in disease. 5th ed. London: Butterworth-Heinemann Ltd.; 1994. 238 р.; Baran R, Sigurgeirsson B. Psoriatic nail disease, a predictor of psoriatic arthritis. Br J Dermatol. 2014;171(5):935–936. https://doi.org/10.1111/bjd.13398Test.; Langley RG, Daudén E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology. 2010;221(Suppl 1):29–42. https://doi.org/10.1159/000316179Test.; Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7(4):317–321. https://doi.org/10.1007/s10227-002-0143-0Test.; Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999;26(8):1752–1756. Available at: https://pubmed.ncbi.nlm.nih.gov/10451073Test/.; Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016;17(1):87–97. https://doi.org/10.1007/s40257-015-0169-xTest.; Pala E, Melikoğlu M, Karaşahin Ö, Alkan Melikoğlu M. The Frequency of Association of Nail Involvement and Psoriatic Arthritis in Psoriasis Patients. Eurasian J Med. 2023;55(2):158–164. https://doi.org/10.5152/eurasianjmed.2023.53Test.; Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128. https://doi.org/10.1111/bjd.13272Test.; Canal-García E, Bosch-Amate X, Belinchón I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliográficas. 2022;113(5):T481–T490. https://doi.org/10.1016/j.ad.2022.01.006Test.; Mease PJ, Liu M, Rebello S, McLean RR, Dube B, Glynn M et al. Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48(4):520–526. https://doi.org/10.3899/jrheum.190923Test.; Peng YT, Yu RT, Chen AJ, Wen ZY, Xu J, Huang K, Wang P. Predicting the Risk of Nail Involvement in Psoriasis Patients: Development and Assessment of a Predictive Nomogram. Diagnostics (Basel). 2023;13(4):633. https://doi.org/10.3390/diagnostics13040633Test.; Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790–794. https://doi.org/10.1093/rheumatology/keh198Test.; Asili P, Tootoonchi N, Nasimi M, Daneshpajooh M, Sedaghatzadeh M, Mirahmad M. Demographic aspects, clinical characteristics, and therapeutic approaches in geriatric psoriasis: A study from a tertiary center. Dermatol Ther. 2022;35(8):e15628. https://doi.org/10.1111/dth.15628Test.; Trettel A, Spehr C, Körber A, Augustin M. The impact of age on psoriasis health care in Germany. J Eur Acad Dermatol Venereol. 2017;31(5):870–875. https://doi.org/10.1111/jdv.14115Test.; Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013;169(2):314–319. https://doi.org/10.1111/bjd.12354Test.; Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, McGonagle D. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–256. https://doi.org/10.1093/rheumatology/kel214Test.; McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal append-age – implications for an improved understanding of the link between psoriasis and arthritis. Dermatology. 2009;218(2):97–102. https://doi.org/10.1159/000182250Test.; Choi JW, Kim BR, Seo E, Youn SW. Identification of nail features associated with psoriasis severity. J Dermatol. 2017;44(2):147–153. https://doi.org/10.1111/1346-8138.13565Test.; Mashal ZR, Elgamal EEA, Zaky MS, Elsaie ML. Dermoscopic Features of Psoriatic Nails and Their Correlation to Disease Severity. Dermatol Res Pract. 2023;2023:4653177. https://doi.org/10.1155/2023/4653177Test.; Lawry M, Daniel CR 3rd. Nails in systemic disease. In: Scher RK, Daniel CR (eds). Nails: Diagnosis, Therapy, Surgery. 3rd ed. Philadelphia: Elsevier Science Limited; 2005. 352 p.; Gregoriou S, Argyriou G, Larios G, Rigopoulos D. Nail disorders and systemic disease: what the nails tell us. J Fam Pract. 2008;57(8):509–514. Available at: https://pubmed.ncbi.nlm.nih.gov/18687226Test/.; Schneider SL, Tosti A. Tips to diagnose uncommon nail disorders. Dermatol Clin. 2015;33(2):197–205. https://doi.org/10.1016/j.det.2014.12.003Test.; van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. Fingernail psoriasis reconsidered: a case-control study. J Am Acad Dermatol. 2013;69(2):245–252. https://doi.org/10.1016/j.jaad.2013.02.009Test.; Marina EM, Botar-Jid C, Bolboaca SD, Roman II, Senila CS, Mihu CM, Tataru DA. Patterns of clinical nail appearances in patients with cutaneous psoriasis. Clujul Med. 2017;90(1):22–27. https://doi.org/10.15386/cjmed-679Test.; Wanniang N, Navya A, Pai V, Ghodge R. Comparative Study of Clinical and Dermoscopic Features in Nail Psoriasis. Indian Dermatol Online J. 2020;11(1):35–40. https://doi.org/10.4103/idoj.IDOJ_51_19Test.; Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis (Auckl). 2017;(7):51–63. https://doi.org/10.2147/PTT.S126281Test.; Arora S, Paul D, Kumar R, Bhatnagar A, Arora G, Mech S, Suhag DK. Study of Nail Psoriasis and Dermoscopic Correlation with Dermoscopic and Modified Dermoscopic Nail Psoriasis Severity Indexes (dNAPSI and dmNAPSI). Dermatol Pract Concept. 2022;12(1):e2022010. https://doi.org/10.5826/dpc.1201a10Test.; Schons KR, Beber AA, Beck Mde O, Monticielo OA. Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. An Bras Dermatol. 2015;90(3):314–319. https://doi.org/10.1590/abd1806-4841.20153736Test.; Chauhan A, Singal A, Grover C, Sharma S. Dermoscopic Features of Nail Psoriasis: An Observational, Analytical Study. Skin Appendage Disord. 2020;6(4):207–215. https://doi.org/10.1159/000508165Test.; Yorulmaz A, Artuz F. A study of dermoscopic features of nail psoriasis. Postepy Dermatol Alergol. 2017;34(1):28–35. https://doi.org/10.5114/ada.2017.65618Test.; Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC. The prevalence of onychomycosis in psoriatic patients: a systematic review. J Eur Acad Dermatol Venereol. 2014;28(5):533–541. https://doi.org/10.1111/jdv.12239Test.; Jendoubi F, Ben Lagha I, Rabhi F, Doss N, Mrabet A, Jaber K, Dhaoui MR. Nail Involvement in Psoriatic Patients and Association with Onychomycosis: Results from a Cross-Sectional Study Performed in a Military Hospital in Tunisia. Skin Appendage Disord. 2019;5(5):299–303. https://doi.org/10.1159/000497825Test.; Lanna C, Zangrilli A, Bavetta M, Campione E, Bianchi L. Efficacy and safety of adalimumab in difficult-to-treat psoriasis. Dermatol Ther. 2020;33(3):e13374. https://doi.org/10.1111/dth.13374Test.; Lanna C, Galluzzi C, Zangrilli A, Bavetta M, Bianchi L, Campione E. Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. J Dermatolog Treat. 2022;33(1):531–534. https://doi.org/10.1080/09546634.2020.1770175Test.; Ковалева ЮС, Ведлер АА, Субботин ЕА, Грибова ГВ. Псориатическая ониходистрофия как маркер тяжести псориаза и сопутствующей коморбидности. Вестник СурГУ. Медицина. 2020;(4):51–57. https://doi.org/10.34822/2304-9448-2020-4-51-57Test.; de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300–303. https://doi.org/10.1159/000246274Test.; Rigopoulos D, Baran R, Chiheb S, Daniel CR 3rd, Di Chiacchio N, Gregoriou S et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus. J Am Acad Dermatol. 2019;81(1):228–240. https://doi.org/10.1016/j.jaad.2019.01.072Test.; Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatol Ther (Heidelb). 2021;11(3):799–831. https://doi.org/10.1007/s13555-021-00523-xTest.; Langley RG, Saurat JH, Reich K. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2012;26(3):373–381. https://doi.org/10.1111/j.1468-3083.2011.04349.xTest.; Laheru D, Antony A, Carneiro S, Di Lernia V, Garg A, Love TJ et al. Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(3):433–437. https://doi.org/10.3899/jrheum.220313Test.; Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483. https://doi.org/10.1111/jdv.15340Test.; Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. 78 с. Режим доступа: https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdfTest.; Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–212. https://doi.org/10.1067/s0190-9622Test(03)00910-1.; Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–966. https://doi.org/10.1111/bjd.17351Test.; Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, Tofani L et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med. 2022;11(9):2631. https://doi.org/10.3390/jcm11092631Test.; Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29(2):353–360. https://doi.org/10.1111/jdv.12553Test.; Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2019;33(11):2168–2178. https://doi.org/10.1111/jdv.15793Test.; Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166(1):179–188. https://doi.org/10.1111/j.1365-2133.2011.10583.xTest.; Кубанов АА, Бакулев АЛ, Самцов АВ, Хайрутдинов ВР, Соколовский ЕВ, Кохан ММ и др. Нетакимаб – новый ингибитор ИЛ-17а: результаты 12 недель клинического исследования III фазы BCD-085-7/PLANETA у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Вестник дерматологии и венерологии. 2019;95(2):15–28. https://doi.org/10.25208/0042-4609-2019-95-2-15-28Test.; Круглова ЛС, Руднева НС, Бакулев АЛ, Хотко АА. Инверсный псориаз и псориаз «трудных» локализаций: эффективность нетакимаба. Медицинский алфавит. 2022;1(27):14–20. https://doi.org/10.33667/2078-5631-2022-27-14-20Test.; Жукова ОВ, Артемьева СИ, Аль-Хаватми АA-ХM. Псориаз ногтей: динамика клинического течения на фоне терапии препаратами ИЛ-17. Медицинский совет. 2022;16(3):38–45. https://doi.org/10.21518/2079-701X-2022-16-3-38-45Test.; Kyriakou A, Zagalioti SC, Trakatelli MG, Fotiadou C, Apalla Z, Lazaridou E, Patsatsi A. Fungal Infections and Nail Psoriasis: An Update. J Fungi (Basel). 2022;8(2):154. https://doi.org/10.3390/jof8020154Test.; https://www.med-sovet.pro/jour/article/view/8139Test

الإتاحة: https://doi.org/10.21518/ms2024-054Test
https://doi.org/10.1111/bjd.13398Test
https://doi.org/10.1159/000316179Test
https://doi.org/10.1007/s10227-002-0143-0Test
https://doi.org/10.1007/s40257-015-0169-xTest
https://doi.org/10.5152/eurasianjmed.2023.53Test
https://doi.org/10.1111/bjd.13272Test
https://doi.org/10.1016/j.ad.2022.01.006Test
https://doi.org/10.3899/jrheum.190923Test
https://doi.org/10.3390/diagnostics13040633Test

المؤلفون: O. V. Zhukova, S. I. Artemyeva, A. Al-Hawatmi, E. A. Pechatnikova

المصدر: Медицинский совет, Vol 0, Iss 13, Pp 18-23 (2022)

مصطلحات موضوعية: psoriasis, psoriatic onychodystrophy, nail psoriasis, il-17а inhibitors, netakimab, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/7005Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/1bacbb246e994775920f69860c321babTest

المؤلفون: Andrey I. Bakulev, Alexey V. Samtsov, Evgeny V. Sokolovskiy, Muza M. Kokhan, Marianna M. Khobeish, Vladislav R. Khairutdinov, Arfenya E. Karamova, Olga U. Olisova, Dmitry V. Ignatiev, Aleksandra N. Nikiforova, Antonina V. Artemeva, Arina V. Zinkina-Orikhan

المصدر: Vestnik Dermatologii i Venerologii, Vol 98, Iss 2, Pp 42-52 (2022)

مصطلحات موضوعية: netakimab, psoriasis, humanized monoclonal antibody, adverse events, Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: https://vestnikdv.ru/jour/article/viewFile/1306/pdfTest; https://doaj.org/toc/0042-4609Test; https://doaj.org/toc/2313-6294Test

الوصول الحر: https://doaj.org/article/78e60d811fc14bc4b9c9d7a250c5497dTest

المؤلفون: O. V. Zhukova, S. I. Artemyeva, A.A.-H.M. Al-Hawatmi

المصدر: Медицинский совет, Vol 0, Iss 3, Pp 38-45 (2022)

مصطلحات موضوعية: psoriasis, nail psoriasis, psoriatic onychodystrophy, netakimab, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6733Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/dc328dd8ea3547f0a1358728ebf893f5Test

المؤلفون: M. I. Kurdina, N. G. Kolenko, М. И. Курдина, Н. Г. Коленько

المصدر: Meditsinskiy sovet = Medical Council; № 14 (2023); 53-60 ; Медицинский Совет; № 14 (2023); 53-60 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: нетакимаб, IL-17 inhibitor, biological therapies, netakimab, ингибитор ИЛ-17, генно-инженерная биологическая терапия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7760/6889Test; Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. https://doi.org/10.1007/s12016-018-8702-3Test.; Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–489. https://doi.org/10.1111/ced.12805Test.; Frez ML, Asawanonda P, Gunasekara C, Koh C, Loo S, Oon HH et al. Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group. J Dermatolog Treat. 2014;25(1):38–45. https://doi.org/10.3109/09546634.2012.742176Test.; Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–142. https://doi.org/10.1016/j.jaad.2015.09.001Test.; Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trüeb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(12):1435–1444. https://doi.org/10.1111/j.1468-3083.2009.03372.xTest.; Bovenschen HJ, Van de Kerkhof PC. Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo, a study on daily clinical practice. J Eur Acad Dermatol Venereol. 2010;24(4):439–444. https://doi.org/10.1111/j.1468-3083.2009.03436.xTest.; Tan J, Thomas R, Wang B, Gratton D, Vender R, Kerrouche N et al. Shortcontact clobetasol propionate shampoo improves scalp psoriasis patients’ quality of life. Cutis. 2009;83(3):157–164. Available at: https://pubmed.ncbi.nlm.nih.gov/19363909Test/.; Papp K, Poulin Y, Barber K, Lynde C, Prinz JC, Berg M et al. Cost-effectiveness evaluation of CPS maintenance in patients with moderate scalp psoriasis a Pan-European analysis. J Eur Acad Dermatol Venereol. 2012;26(11):1407–1414. https://doi.org/10.1111/j.1468-3083.2011.04305.xTest.; Leon A, Rosen JD, Hashimoto T, Fostini AC, Paus R, Yosipovitch G. Itching for an answer: A review of potential mechanisms of scalp itch in psoriasis. Exp Dermatol. 2019;28(12):1397–1404. https://doi.org/10.1111/exd.13947Test.; Komiya E, Tominaga M, Kamata Y, Suga Y, Takamori K. Molecular and Cellular Mechanisms of Itch in Psoriasis. Int J Mol Sci. 2020;21(21):8406. https://doi.org/10.3390/ijms21218406Test.; Nattkemper LA, Lipman ZM, Ingrasci G, Maldonado C, Garces JC, Loayza E, Yosipovitch G. Neuroimmune Mediators of Pruritus in Hispanic Scalp Psoriatic Itch. Acta Derm Venereol. 2023;103:adv4463. https://doi.org/10.2340/actadv.v103.4463Test.; Aldredge LM, Higham RC. Manifestations and Management of Difficult-toTreat Psoriasis. J Dermatol Nurses’ Association. 2018;10(4):189–197. https://doi.org/10.1097/JDN.0000000000000418Test.; Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392–398. https://doi.org/10.5114/reum.2018.80718Test.; Alsenaid A, Ezmerli M, Srour J, Heppt M, Illigens BM, Prinz JC. Biologics and small molecules in patients with scalp psoriasis: a systematic review. J Dermatol Treat. 2020;33(1):473–482. https://doi.org/10.1080/09546634.2020.1770167Test.; Camela E, Ocampo-Garza SS, Cinelli E, Villani A, Fabbrocini G, Megna M. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatol Ther. 2021;34(2):e14857. https://doi.org/10.1111/dth.14857Test.; Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN, Psoriasis Patient Interview Study Group. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Treat. 2016;27(1):19–26. https://doi.org/10.3109/09546634.2015.1044492Test.; Pollo CF, Miot HA, Matos TDS, de Souza JM, Jorge MFS, Miot LDB, Meneguin S. Prevalence and factors associated with depression and anxiety in patients with psoriasis. J Clin Nurs. 2021;30(3–4):572–580. https://doi.org/10.1111/jocn.15577Test.; Liang SE, Cohen JM, Ho RS. Psoriasis and suicidality: A review of the literature. Dermatol Ther. 2019;32(1):e12771. https://doi.org/10.1111/dth.12771Test.; Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I et al. Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239(4):621–634. https://doi.org/10.1159/000528945Test.; Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis (Auckl). 2016;6:33–40. https://doi.org/10.2147/PTT.S85330Test.; George SM, Taylor MR, Farrant PB. Psoriatic alopecia. Clin Exp Dermatol. 2015;40(7):717–721. https://doi.org/10.1111/ced.12715Test.; Patrizi A, Venturi M, Scorzoni R, Pazzaglia M, Malavolta N, Bardazzi F. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis?. G Ital Dermatol Venereol. 2014;149(2):177184. Available at: https://pubmed.ncbi.nlm.nih.gov/24819637Test/.; Karmacharya P, Wright K, Achenbach SJ, Crowson CS, Ogdie A, Bekele D et al. Time to transition from psoriasis to psoriatic arthritis: A populationbased study. Semin Arthritis Rheum. 2022;52:151949. https://doi.org/10.1016/j.semarthrit.2021.12.013Test.; Ghafoor R, Patil A, Yamauchi P, Weinberg J, Kircik L, Grabbe S, Goldust M. Treatment of Scalp Psoriasis. J Drugs Dermatol. 2022;21(8):833–837. https://doi.org/10.36849/JDD.6498Test.; Coates LC, Kavanaugh A, Mease P, Soriano ER, Acosta-Felquer ML, Armstrong AW et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071. https://doi.org/10.1002/art.39573Test.; Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790. https://doi.org/10.1111/jdv.14114Test.; Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. https://doi.org/10.1016/j.jaad.2018.11.057Test.; Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. International Psoriasis Council Board Members and Councilors. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. https://doi.org/10.1016/j.jaad.2019.08.026Test.; Жуков АС, Хотко АА, Хайрутдинов ВР, Самцов АВ. Профили больных псориазом для назначения генно-инженерной биологической терапии – клиническое обоснование. Вестник дерматологии и венерологии. 2020;96(1):58–66. https://doi.org/10.25208/vdv550-2020-96-1-58-66Test; Кубанов АА, Бакулев АЛ, Самцов АВ, Хайрутдинов ВР, Соколовский ЕВ, Кохан ММ и др. Нетакимаб – новый ингибитор ИЛ-17а: результаты 12 нед. клинического исследования III фазы BCD-085-7/PLANETA у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Вестник дерматологии и венерологии. 2019;95(2):15–28. https://doi.org/10.25208/0042-4609-2019-95-2-15-28Test.; Бакулев АЛ, Самцов АВ, Соколовский ЕВ, Кохан ММ, Хобейш ММ, Хайрутдинов ВР и др. Эффективность и безопасность двухлетней терапии нетакимабом у пациентов со среднетяжелым и тяжелым бляшечным псориазом в рамках рандомизированного двойного слепого плацебо-контролируемого клинического исследования BCD-085-7/PLANETA.; Круглова ЛС, Руднева НС, Бакулев АЛ, Хотко АА. Инверсный псориаз и псориаз «трудных» локализаций: эффективность нетакимаба. Медицинский ал - фавит. 2022;1(27):14–20. https://doi.org/10.33667/2078-5631-2022-27-14-20Test.; Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. 78 с. Режим доступа: https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdfTest.; Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–674. https://doi.org/10.1016/j.jaad.2017.05.033Test.; Feldman SR, Green L, Kimball AB, Siu K, Zhao Y, Herrera V, Nyirady J, Alexis AF. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017;28(8):716–721. https://doi.org/10.1080/09546634.2017.1329502Test.; https://www.med-sovet.pro/jour/article/view/7760Test

الإتاحة: https://doi.org/10.21518/ms2023-277Test
https://doi.org/10.1007/s12016-018-8702-3Test
https://doi.org/10.1111/ced.12805Test
https://doi.org/10.3109/09546634.2012.742176Test
https://doi.org/10.1016/j.jaad.2015.09.001Test
https://doi.org/10.1111/j.1468-3083.2009.03372.xTest
https://doi.org/10.1111/j.1468-3083.2009.03436.xTest
https://doi.org/10.1111/j.1468-3083.2011.04305.xTest
https://doi.org/10.1111/exd.13947Test
https://doi.org/10.3390/ijms21218406Test

المؤلفون: S. A. Lapshina, A. R. Garaeva, Z. N. Gabdullina, E. V. Sukhorukova, D. I. Abdulganieva, С. А. Лапшина, А. Р. Гараева, З. Н. Габдуллина, Е. В. Сухорукова, Д. И. Абдулганиева

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2023); 128–135 ; Медицинский Совет; № 10 (2023); 128–135 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ингибитор интерлейкина-17, netakimab, spondyloarthritis, without biological remission, biological therapy, interleukin-17 inhibitor, спондилоартрит, безбиологическая ремиссия, нетакимаб, биологическая терапия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7649/6782Test; Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Гайдукова И.З., Годзенко А.А. и др. О терминологии спондилоартритов. Научно- практическая ревматология. 2015;53(6):657–660. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2159Test.; Эрдес Ш.Ф. Последние достижения и перспективы терапии аксиального спондилоартрита/анкилозирующего спондилита. Современная ревматология. 2021;15(2):94–105. https://doi.org/10.14412/1996-7012-2021-2-94-105Test.; Sofia Ramiro S., Nikiphorou E., Sepriano A., Ortolan A., Webers C., Baraliakos X. et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34. https://doi:10.1136/ard-2022-223296Test.; Гайдукова И.З., Ребров А.П., Лапшина С.А., Оттева Э.Н., Дубинина Т.В., Бадокин В.В. и др. Применение нестероидных противовоспалительных препаратов и генно- инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474–484. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2428Test.; Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., Яхно Н.Н., Арутюнов Г.П. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(1 Suppl.):1–29. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2536Test.; Van der Heijde D., Ramiro S., Landewé R., Baraliakos X., Van den Bosch F., Sepriano A. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. https://doi.org/10.1136/annrheumdis-2016-210770Test.; Лапшина С.А., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Гайдукова И.З. и др. Ингибиторы фактора некроза опухоли А в лечении аксиальных спондилоартритов, включая анкилозирующий спондилит. Научно-практическая ревматология. 2016;54(1 Suppl.):75–79. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2257Test.; Ward M.M., Deodhar A., Gensler L.S., Dubreuil M., Yu D., Khan M.A. et al. 2019 update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographicaxial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–1613. https://doi.org/10.1002/art.41042Test.; Baraliakos X., Listing J., Brandt J., Zink A., Alten R., Burmester G. et al. Clinical response to discontinuation of anti- TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439–R444. https://doi.org/10.1186/ar1693Test.; Baraliakos X., Listing J., Rudwaleit M., Brandt J., Alten R., Burmester G. et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007;34(3):510–515. Available at: https://www.jrheum.org/content/34/3/510.longTest.; Zhao M.J., Zhang P.P., Fang L.K., Luo Z., Gu J., Lin Z. Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years’ following-up study. Clin Rheumatol. 2018;37(1):87–92. https://doi.org/10.1007/s10067-017-3763-xTest.; Chen M.H., Lee M.H., Liao H.T., Chen W.S., Lai C.C., Tsai C.Y. Health-r elated quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. Clin Rheumatol. 2018;37(2):429–438. https://doi.org/10.1007/s10067-017-3965-2Test.; Landewé R., Sieper J., Mease P., Inman R.D., Lambert R.G., Deodhar A. et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-b lind study. Lancet. 2018;392(10142):134–144. https://doi.org/10.1016/S01406736Test(18)31362-X.; Sebastian A., Wojtala P., Lubiński Ł., Mimier M., Chlebicki A., Wiland P. Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy. Reumatologia. 2017;55(4):157–162. https://doi.org/10.5114/reum.2017.69775Test.; Song I.H., Althoff C.E., Haibel H., Hermann K.G., Poddubnyy D., Listing J. et al. Frequency and duration of drugfree remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7):1212–1215. https://doi.org/10.1136/annrheumdis-2011-201010Test.; Michielsens C.A.J., Boers N., den Broeder N., Wenink M.H., van der Maas A., Mahler E.A.M. et al. Dose reduction and withdrawal strategy for TNFinhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. Trials. 2020;21(1):90. https://doi.org/10.1186/s13063-019-4000-5Test.; Park J.W., Kim H.A., Shin K., Park Y.B., Kim T.H., Song Y.W., Lee E.Y. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study. ArthritisRes Ther. 2019;21(1):163. https://doi.org/10.1186/s13075019-1943-6Test.; Michielsens C.A.J., den Broeder N., Mulder M.L.M., van den Hoogen F.H.J., Verhoef L.M., den Broeder A.A. Tumour necrosis factor inhibitor dose adaptation MEDITSINSKIY SOVET in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. Rheumatology (Oxford). 2022;61(6):2307–2315. https://doi.org/10.1093/rheumatology/keab741Test.; Tang C., Chen F., Zheng S., Wu L., Chen S., Zhu J., Li J. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study]. Nan Fang Yi Ke Da Xue Xue Bao. 2021;41(5):633–639. https://doi.org/10.12122/j.issn.1673-4254.2021.05.01Test.; Mo Q., Dong Y., Ye C., Zhong J., Cai S., Wang M., Dong L. Structural Lesion Progression of the Sacroiliac Joint and Clinical Features in axSpA During TNFi Reduction: A Retrospective Cohort Study. Front Med (Lausanne). 2021;8:781088. https://doi.org/10.3389/fmed.2021.781088Test.; Landewé R.B., Gensler L.S., Poddubnyy D., Rahman P., Hojnik M., Li X. et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo- controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis. 2021;80(8):1022–1030. https://doi.org/10.1136/annrheumdis-2020-219717Test.; Coates L.C., Pillai S.G., Tahir H., Valter I., Chandran V., Kameda H. et al. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-B lind Withdrawal Study. Arthritis Rheumatol. 2021;73(9):1663–1672. https://doi.org/10.1002/art.41716Test.; Мазуров В.И., Гайдукова И.З, Эрдес Ш.3., Дубинина Т.В., Пристром А.М., Кундер Е.В. и др. Эффективность и безопасность нетакимаба, моноклонального антитела против интерлейкина-17А, у пациентов с активным анкилозирующим спондилитом. Результаты международного многоцентрового рандомизированного двой ного слепого клинического исследования III фазы BCD-085-5/ASTERA. Научно- практическая ревматология. 2020;58(4):376–386. https://doi.org/10.47360/1995-4484-2020-376-386Test.; Хотко А.А., Круглова Л.С., Помазанова М.Ю., Хотко Р.А. Эффективность препарата нетакимаб в реальной клинической практике у пациентов с тяжелыми формами псориаза. Медицинский алфавит. 2020;(6):28–33. https://doi.org/10.33667/2078-5631-2020-6-28-33Test.; Коротаева Т.В., Самцов А.В., Хайрутдинов В.Р., Бакулев А.Л., Младов В.В., Еремеева А.В., Зинкина-Орихан А.В. Эффективность нетакимаба у пациентов с псориатическим артритом, ранее не получавших ингибиторы фактора некроза опухоли a: субанализ результатов исследования PATERA. Consilium Medicum. 2020;22(7):14–19. https://doi.org/10.26442/20751753.2020.7.200319Test.; Van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–368. https://doi.org/10.1002/art.1780270401Test.; Гайдукова И.З., Ребров А.П., Коротаева Т.В., Дубинина Т.В., Оттева Э.Н., Бадокин В.В. и др. Ремиссия при аксиальных спондилоартритах – определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»). Научно- практическая ревматология. 2018;56(1):10–14. Режим доступа: https://rsp.mediar-press.net/rsp/article/view/2493Test.; Gossec L., Portier A., Landewé R., Etcheto A., Navarro- Compán V., Kroon F. et al. Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum Dis. 2016;75(6):991–996. https://doi.org/10.1136/annrheumdis-2015-208593Test.; Дубинина Т.В., Гайдукова И.З., Годзенко А.А., Лапшина С.А., Ребров А.П., Румянцева О.А. и др. Рекомендации по оценке активности болезни и функционального состояния больных анкилозирующим спондилитом в клинической практике. Научно- практическая ревматология. 2017;55(4):344–350. https://doi.org/10.14412/1995-4484-2017-344-350Test.; Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing spondylitis disease activity score (ASDAS), Ankylosing spondylitis quality of life scale (ASQoL), Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath ankylosing spondylitis metrology index (BASMI), Dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQS). Arthritis Care Res (Hoboken). 2011;63(11 Suppl.):47–58. https://doi.org/10.1002/acr.20575Test.; Carron P., Varkas G., Renson T., Colman R., Elewaut D., Van den Bosch F. High Rate of Drug- Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis. Arthritis Rheumatol. 2018;70(11):1769–1777. Available at: https://pubmed.ncbi.nlm.nih.gov/29806090Test.; https://www.med-sovet.pro/jour/article/view/7649Test

الإتاحة: https://doi.org/10.21518/ms2023-200Test
https://doi.org/10.14412/1996-7012-2021-2-94-105Test
https://doi.org/10.1136/ard-2022-223296Test
https://doi.org/10.1136/annrheumdis-2016-210770Test
https://doi.org/10.1002/art.41042Test
https://doi.org/10.1186/ar1693Test
https://doi.org/10.1007/s10067-017-3763-xTest
https://doi.org/10.1007/s10067-017-3965-2Test
https://doi.org/10.1016/S01406736Test(18)31362-X
https://doi.org/10.5114/reum.2017.69775Test

المؤلفون: E. V. Svechnikova, S. E. Zhufina, M. A. Morzhanaeva, Е. В. Свечникова, С. Е. Жуфина, М. А. Моржанаева

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2023); 69-74 ; Медицинский Совет; № 2 (2023); 69-74 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: нетакимаб, basic therapy, genetically engineered biological therapy, netakimab, базисная терапия, генно-инженерная биологическая терапия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7390/6591Test; Kaushik S.B., Lebwohl M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057Test.; Ito T., Takahashi H., Kawada A., Iizuka H., Nakagawa H., Japanese Society for Psoriasis Research. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol. 2018;45(3):293–301. https://doi.org/10.1111/1346-8138.14105Test.; Kamiya K., Kishimoto M., Sugai J., Komine M., Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347. https://doi.org/10.3390/ijms20184347Test.; Swindell W.R., Johnston A., Xing X., Voorhees J.J., Elder J.T., Gudjonsson J.E. Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One. 2013;8(11):e79253. https://doi.org/10.1371/journal.pone.0079253Test.; Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. https://doi.org/10.1056/NEJMra0804595Test.; Kolbinger F., Loesche C., Valentin M.A., Jiang X., Cheng Y., Jarvis P. et al. β‐Defensin 2 is a responsive biomarker of IL‐17A‐driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923–32.e8. https://doi.org/10.1016/j.jaci.2016.06.038Test.; Korman N.J. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. https://doi.org/10.1111/bjd.18245Test.; Griffiths C.E.M., Fava M., Miller A.H., Russell J., Ball S.G., Xu W. et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate‐to‐severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260–267. https://doi.org/10.1159/000479163Test.; Wu J.J., Sundaram M., Cloutier M., Gauthier-Loiselle M., Guerin A., Sigh R., Ganduli A. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor‐α inhibitors versus phototherapy: an observational cohort study. J Am Acad Dermatol. 2018;79(1):60–68. https://doi.org/10.1016/j.jaad.2018.02.050Test.; Wu J.J., Joshi A.A., Reddy S.P., Batech M., Egeberg A., Ahlehoff O., Mehta N.N. Anti‐inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(8):1320–1326. https://doi.org/10.1111/jdv.14951Test.; Bellinato F., Gisondi P., Girolomoni G. Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. Biologics. 2021;(15):247–253. https://doi.org/10.2147/BTT.S290309Test.; Kostareva O., Svoeglazova A., Kolyadenko I., Nikulin A., Evdokimov S., Dzhus U. et al. Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A V HH Domain. Int J Mol Sci. 2022;23(23):14904. https://doi.org/10.3390/ijms232314904Test.; Puig L., Bakulev A.L., Kokhan M.M., Samtsov A.V., Khairutdinov V.R., Morozova M.A. et al. Efficacy and Safety of Netakimab, A Novel AntiIL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind PlaceboControlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021;11(4):1319–1332. https://doi.org/10.1007/s13555-021-00554-4Test.; https://www.med-sovet.pro/jour/article/view/7390Test

الإتاحة: https://doi.org/10.21518/ms2023-012Test
https://doi.org/10.1016/j.jaad.2018.06.057Test
https://doi.org/10.1111/1346-8138.14105Test
https://doi.org/10.3390/ijms20184347Test
https://doi.org/10.1371/journal.pone.0079253Test
https://doi.org/10.1056/NEJMra0804595Test
https://doi.org/10.1016/j.jaci.2016.06.038Test
https://doi.org/10.1159/000479163Test
https://doi.org/10.1016/j.jaad.2018.02.050Test
https://doi.org/10.1111/jdv.14951Test

المؤلفون: T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. A. Sevastyanova, A. V. Eremeeva

المصدر: Научно-практическая ревматология, Vol 59, Iss 1, Pp 47-55 (2021)

مصطلحات موضوعية: netakimab, psoriatic arthritis, interleukin-17 inhibitors, Diseases of the musculoskeletal system, RC925-935

وصف الملف: electronic resource

العلاقة: https://rsp.mediar-press.net/rsp/article/view/2989Test; https://doaj.org/toc/1995-4484Test; https://doaj.org/toc/1995-4492Test

الوصول الحر: https://doaj.org/article/4cf1afa40e2e4cf69285a9061fcc7d8fTest